OTLK
OTLK
NASDAQ · Biotechnology

Outlook Therapeutics Inc

$0.21
+0.00 (+1.65%)
As of Apr 1, 3:55 PM ET ·
Financial Highlights (FY 2026)
Revenue
3.44M
Net Income
-152,160,195
Gross Margin
4.0%
Profit Margin
-4,416.2%
Rev Growth
-22.9%
D/E Ratio
1.25
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 4.0% 4.0% 56.9% 56.9%
Operating Margin -4,744.2% -4,269.8% -19.4% -22.9%
Profit Margin -4,416.2% -4,195.4% -21.7% -24.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 3.44M 4.47M 5.83M 5.25M
Gross Profit 139.5K 181.0K 3.32M 2.99M
Operating Income -163,369,612 -190,778,059 -1,128,182 -1,200,249
Net Income -152,160,195 -177,688,043 -1,267,217 -1,265,078
Gross Margin 4.0% 4.0% 56.9% 56.9%
Operating Margin -4,744.2% -4,269.8% -19.4% -22.9%
Profit Margin -4,416.2% -4,195.4% -21.7% -24.1%
Rev Growth -22.9% -22.9% +8.5% -2.3%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 4.94M 4.94M 11.21M 13.12M
Total Equity 3.95M 3.95M 16.90M 15.49M
D/E Ratio 1.25 1.25 0.66 0.85
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -154,840,385 -190,863,326 -1,820,131 -1,644,658
Free Cash Flow -1,133,887 -1,157,439